Summary
Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company that develops and manufactures monoclonal antibodies for the treatment and diagnosis of cancer. The company’s products include Bavituximab, PGN650 and Cotara. Peregrine’s Bavituximab is a monoclonal antibody that binds to a basic component of the cell structure called a phospholipid. Its Cotara is for Phase III clinical development for the treatment of glioblastoma multiforme (GBM). The company utilizes technologies such as phosphatidylserine (PS)-targeting therapy for cancers and viral diseases and tumor necrosis therapy. Peregrine is headquartered in Tustin, California, the US.
Peregrine Pharmaceuticals, Inc. (PPHM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Peregrine Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 9
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 12
Peregrine Pharma Expands its Agreement with AstraZeneca 13
Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 14
Peregrine Pharma Amends Its Research Collaboration With Affitech 15
Avid Bioservices Extends Manufacturing And Supply Agreement With Halozyme Therapeutics 16
Licensing Agreements 17
Peregrine Pharma Amends Its Licensing Agreement With Affitech 17
Peregrine Pharma Enters Into Licensing Agreement With Stason Pharma 19
Equity Offering 20
Peregrine Pharma to Raise USD30 Million in Public Offering of Shares 20
Peregrine Pharma to Raise USD12.3 Million in Public Offering of Shares 22
Peregrine Pharma Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Series E Preferred Stock For US$19.4 Million 24
Peregrine Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 26
Peregrine Pharma Completes Private Placement Of Shares For US$14 Million 27
Peregrine Pharma Files Registration Statement For Private Placement Of Common Stock For US$75 Million 28
Peregrine Pharma Completes Private Placement Of Shares For US$7 Million 30
Peregrine Pharma Completes Second Tranche Of Public Offering Of Common Stock For US$2.35 Million 32
Peregrine Pharma Completes Public Offering Of US$14 Million 34
Peregrine Pharma Completes Private Placement Of US$25 Million 36
Peregrine Pharmaceuticals, Inc. - Key Competitors 38
Key Employees 39
Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41
List of Tables
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Peregrine Pharmaceuticals, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Peregrine Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 9
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 12
Peregrine Pharma Expands its Agreement with AstraZeneca 13
Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 14
Peregrine Pharma Amends Its Research Collaboration With Affitech 15
Avid Bioservices Extends Manufacturing And Supply Agreement With Halozyme Therapeutics 16
Peregrine Pharma Amends Its Licensing Agreement With Affitech 17
Peregrine Pharma Enters Into Licensing Agreement With Stason Pharma 19
Peregrine Pharma to Raise USD30 Million in Public Offering of Shares 20
Peregrine Pharma to Raise USD12.3 Million in Public Offering of Shares 22
Peregrine Pharma Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Series E Preferred Stock For US$19.4 Million 24
Peregrine Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 26
Peregrine Pharma Completes Private Placement Of Shares For US$14 Million 27
Peregrine Pharma Files Registration Statement For Private Placement Of Common Stock For US$75 Million 28
Peregrine Pharma Completes Private Placement Of Shares For US$7 Million 30
Peregrine Pharma Completes Second Tranche Of Public Offering Of Common Stock For US$2.35 Million 32
Peregrine Pharma Completes Public Offering Of US$14 Million 34
Peregrine Pharma Completes Private Placement Of US$25 Million 36
Peregrine Pharmaceuticals, Inc., Key Competitors 38
Peregrine Pharmaceuticals, Inc., Key Employees 39
Peregrine Pharmaceuticals, Inc., Subsidiaries 40
List of Figures
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Peregrine Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Peregrine Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 9
